IDEAS home Printed from https://ideas.repec.org/r/sae/medema/v13y1993i2p89-102.html
   My bibliography  Save this item

The Beaver Dam Health Outcomes study

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Daniel Sperber & Alan Shiell & Ken Fyie, 2010. "The cost‐effectiveness of a law banning the use of cellular phones by drivers," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1212-1225, October.
  2. Xiao Zang & Houlin Tang & Jeong Eun Min & Diane Gu & Julio S G Montaner & Zunyou Wu & Bohdan Nosyk, 2016. "Cost-Effectiveness of the ‘One4All’ HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-17, November.
  3. Laura Panattoni & Paul Brown & Braden Ao & Mark Webster & Patrick Gladding, 2012. "The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes," PharmacoEconomics, Springer, vol. 30(11), pages 1067-1084, November.
  4. Harris, Ryan A. & Nease, Robert Jr., 1997. "The importance of patient preferences for comorbidities in cost-effectiveness analyses," Journal of Health Economics, Elsevier, vol. 16(1), pages 113-119, February.
  5. Thi-Phuong-Lan Nguyen & Paul F M Krabbe & Thi-Bach-Yen Nguyen & Catharina C M Schuiling-Veninga & E Pamela Wright & Maarten J Postma, 2015. "Utilities of Patients with Hypertension in Northern Vietnam," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-9, October.
  6. Mengjun Wu & John Brazier & Benjamin Kearns & Clare Relton & Christine Smith & Cindy Cooper, 2015. "Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 141-151, March.
  7. Patricia Vold Pepper & Douglas K. Owens, 2002. "Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults," Medical Decision Making, , vol. 22(1_suppl), pages 45-57, September.
  8. Costa-Font, Montserrat & Costa-Font, Joan, 2009. "Heterogeneous 'adaptation' and 'income effects' across self-reported health distribution?," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 38(4), pages 574-580, August.
  9. Trude Arnesen & Mari Trommald, 2005. "Are QALYs based on time trade‐off comparable? – A systematic review of TTO methodologies," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 39-53, January.
  10. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
  11. Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
  12. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
  13. Kibum Kim & Gwendolyn A McMillin & Philip S Bernard & Srinivas Tantravahi & Brandon S Walker & Robert L Schmidt, 2019. "Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-21, December.
  14. Joshua T. Cohen & John D. Graham, 2003. "A Revised Economic Analysis of Restrictions on the Use of Cell Phones While Driving," Risk Analysis, John Wiley & Sons, vol. 23(1), pages 5-17, February.
  15. Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette, 2006. "Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada," PharmacoEconomics, Springer, vol. 24(8), pages 815-830, August.
  16. Smita Nayak & Mark S Roberts & Susan L Greenspan, 2012. "Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-7, March.
  17. Sherine E. Gabriel & Terry S. Kneeland & L. Joseph Melton & Megan M. Moncur & Bruce Ettinger & Anna N.A. Tosteson, 1999. "Health-related Quality of Life in Economic Evaluations for Osteoporosis," Medical Decision Making, , vol. 19(2), pages 141-148, April.
  18. John Anderson & Robert Kaplan & Christopher Ake, 2004. "Arthritis Impact on U.S. Life Quality: Morbidity and Mortality Effects From National Health Interview Survey Data 1986–1988 and 1994 Using QWBX1 Estimates of Well-Being," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 69(1), pages 67-91, October.
  19. James F Burke & Kenneth M Langa & Rodney A Hayward & Roger L Albin, 2014. "Modeling Test and Treatment Strategies for Presymptomatic Alzheimer Disease," PLOS ONE, Public Library of Science, vol. 9(12), pages 1-20, December.
  20. Louis S. Matza & Katherine J. Kim & Holly Yu & Katherine A. Belden & Antonia F. Chen & Mark Kurd & Bruce Y. Lee & Jason Webb, 2019. "Health state utilities associated with post-surgical Staphylococcus aureus infections," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 819-827, August.
  21. William M Reichmann & Jeffrey N Katz & Elena Losina, 2011. "Differences in Self-Reported Health in the Osteoarthritis Initiative (OAI) and Third National Health and Nutrition Examination Survey (NHANES-III)," PLOS ONE, Public Library of Science, vol. 6(2), pages 1-7, February.
  22. Hans-Helmut König & Oliver Günther & Matthias Angermeyer & Christiane Roick, 2009. "Utility Assessment in Patients with Mental Disorders," PharmacoEconomics, Springer, vol. 27(5), pages 405-419, May.
  23. William Hollingworth & Richard A. Deyo & Sean D. Sullivan & Scott S. Emerson & Darryl T. Gray & Jeffrey G. Jarvik, 2002. "The practicality and validity of directly elicited and SF‐36 derived health state preferences in patients with low back pain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 71-85, January.
  24. Susan T. Stewart & Rebecca M. Woodward & Allison B. Rosen & David M. Cutler, 2005. "A Proposed Method for Monitoring U.S. Population Health: Linking Symptoms, Impairments, and Health Ratings," NBER Working Papers 11358, National Bureau of Economic Research, Inc.
  25. Maria Biasutti & Natacha Dufour & Clotilde Ferroud & William Dab & Laura Temime, 2012. "Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer's Disease," PLOS ONE, Public Library of Science, vol. 7(4), pages 1-14, April.
  26. Burstrom, Kristina & Johannesson, Magnus & Diderichsen, Finn, 2001. "Health-related quality of life by disease and socio-economic group in the general population in Sweden," Health Policy, Elsevier, vol. 55(1), pages 51-69, January.
  27. J. Kirsch & A. McGuire, 2000. "Establishing health state valuations for disease specific states: an example from heart disease," Health Economics, John Wiley & Sons, Ltd., vol. 9(2), pages 149-158, March.
  28. Erik Nord & Paul Menzel & Jeff Richardson, 2003. "The value of life: individual preferences and social choice. A comment to Magnus Johannesson," Health Economics, John Wiley & Sons, Ltd., vol. 12(10), pages 873-877, October.
  29. W. Groot & H. M. van den Brink, 2008. "Health-adjusted life expectancy of the British population," Applied Economics, Taylor & Francis Journals, vol. 40(11), pages 1373-1386.
  30. Joyce H S You & Kia K N Tsui & Raymond S M Wong & Gergory Cheng, 2012. "Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-9, June.
  31. Groot, Wim, 2000. "Adaptation and scale of reference bias in self-assessments of quality of life," Journal of Health Economics, Elsevier, vol. 19(3), pages 403-420, May.
  32. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
  33. Young, Tracey A. & Yang, Y & Brazier, J & Tsuchiya, A & Coyne, K, 2008. "Making Rasch decisions: the use of Rasch analysis in the construction of preference based health related quality of life instruments," MPRA Paper 29828, University Library of Munich, Germany.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.